HopeStage
Back to all studies
Not Yet RecruitingNCT07296094

Psilocybin-Assisted Psychotherapy for the Treatment of Severe Addiction

Medication studyAges 18–65United States
The study in practice

Understand this study

Who could participate?

Listed age limits: 18 years to 65 years.

Listed locations
BostonSee all locations and recruitment
Study phase
Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.

Get this study by email

HopeStage may email me about this study.
Loading the security check...

What to know before participating

A point to clarify

This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?

Study clarity

Things to check before joining

Study start dateEstimated: November 15, 2026
Recruitment status
Not Yet Recruiting
Enrollment listed in the registry
36
Sponsor
Brigham and Women's Hospital
Sponsor type
Hospital / academic medical center
Study type
Drug
Intervention type
Drug
Study phase
Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
Locations
United States
Age range
From 18 Years to 65 Years
Official registry ID
NCT07296094
Official title
Show the full official title

Psilocybin-Assisted Psychotherapy for the Treatment of Severe Alcohol Use Disorder: A Double-Blind, Dose-Comparison Concurrent Control Randomized Trial

Recruitment & locations

Not yet recruiting

Boston

Interested in joining this study?

HopeStage may email me about this study.
Loading the security check...
FAQ

Questions about this study

Who is behind this study?

The study sponsor is Brigham and Women's Hospital, a hospital or academic medical center.

Does this study involve medication?

Yes. The study involves medication, including Psilocybin.

Who can participate?

Listed age limits: 18 years to 65 years.

Is this study still recruiting?

The registry lists this study as not yet recruiting.

Want to explore more studies?

Explore studies